Lenvatinib is effective in advanced medullary thyroid cancer
Letting the patient know that multi‑targeted tyrosine‑kinase inhibitors such as Lenvatinib are a useful treatment option for metastatic medullary thyroid cancer.
Lenvatinib, a multi‑targeted tyrosine‑kinase inhibitor, was evaluated in a Phase 2 study of 59 patients with unresectable or metastatic medullary thyroid cancer (MTC). Treatment was given at 24 mg daily for 8 28‑day cycles with dose reductions for toxicity. Of the patients who completed the 8 cycles, 44 % achieved an objective response (36 % response rate). Both calcitonin and CEA levels fell in all treated subjects. Median progression‑free survival was 9 months. Toxicity led to dose reductions in 60 % of patients and discontinuation in 24 %.
MTC is a rare thyroid cancer that does not respond to radioactive iodine, so data suggesting a therapeutic benefit from Lenvatinib provides a new, FDA‑approved option for patients whose disease is not amenable to surgery or I‑131.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management